Edwards Lifesciences (EWLS) Stock Overview
Provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EWLS from our risk checks.
EWLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$74.82 |
| 52 Week High | US$75.24 |
| 52 Week Low | US$59.37 |
| Beta | 0.97 |
| 1 Month Change | 6.44% |
| 3 Month Change | 8.31% |
| 1 Year Change | 9.34% |
| 3 Year Change | 1.03% |
| 5 Year Change | 7.65% |
| Change since IPO | 8.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| EWLS | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 1.2% | 2.2% | 2.8% |
| 1Y | 9.3% | -0.8% | 32.0% |
Return vs Industry: EWLS exceeded the Austrian Medical Equipment industry which returned -1.3% over the past year.
Return vs Market: EWLS underperformed the Austrian Market which returned 32.9% over the past year.
Price Volatility
| EWLS volatility | |
|---|---|
| EWLS Average Weekly Movement | 3.6% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 5.5% |
| 10% least volatile stocks in AT Market | 2.2% |
Stable Share Price: EWLS has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: EWLS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 15,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EWLS fundamental statistics | |
|---|---|
| Market cap | €43.41b |
| Earnings (TTM) | €1.16b |
| Revenue (TTM) | €5.07b |
Is EWLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EWLS income statement (TTM) | |
|---|---|
| Revenue | US$5.88b |
| Cost of Revenue | US$1.28b |
| Gross Profit | US$4.60b |
| Other Expenses | US$3.26b |
| Earnings | US$1.34b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.31 |
| Gross Margin | 78.19% |
| Net Profit Margin | 22.81% |
| Debt/Equity Ratio | 5.9% |
How did EWLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/27 21:50 |
| End of Day Share Price | 2025/11/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Edwards Lifesciences Corporation is covered by 56 analysts. 32 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |